Antithymocyte globulin (ATG) treatment prevents graft failure and results in a low incidence of GVHD, but an increased risk of relapse could be expected as a consequence of reduced GVHD. From September 1995 to June 2001, 28 consecutive chronic myeloid leukemia (CML) patients underwent unrelated bone marrow transplants: 21 were in chronic phase (CP) and seven in advanced phase (AP). Median age was 35.5 years (range 20-50). HLA typing was based on high-resolution molecular techniques; in eight cases there were one or more allele mismatches. The preparative regimen consisted of TBI, EDX 120 mg/kg and rabbit ATG 15 mg/kg. All patients engrafted and no rejection occurred. Acute GVHD grade III-IV occurred in six patients (21%). Chronic GVHD occurred in 10 (40%) and it was extensive in one. Four out of seven patients transplanted in AP had a hematological relapse. Of 21 in CP, there was one cytogenetic and one molecular relapse: these two patients are now in complete remission with imatinib mesylate. With a median follow-up of 45.7 months, the 5-year survival is 76.2% for those transplanted in CP. These data demonstrate that transplants performed in CP, with low-dose ATG, are associated with a good outcome, low incidence of GVHD and no increase of relapse.
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12-14 A dose-dependent effect of ATG has not clearly been shown, but an increased risk of relapse could be expected as a consequence of reduced GVHD. 15, 16 Furthermore, the different types of most commonly used ATG differ profoundly in their antibody specificities 17 and it is neither possible nor correct to make comparisons about equivalence of doses.
With the aim of maintaining the anti-GVHD effect of ATG without increasing the risk of relapse, we added low-dose rabbit ATG in the preparative regimen for unrelated transplants and we report here our experience in CML.
Patients and methods
From September 1995 to June 2001, 28 CML patients underwent allogeneic BMT from unrelated donors at the Institute of Hematology 'L and A Sera`gnoli' of Bologna, Italy.
The CML diagnosis was based on the classical hematological findings and the demonstration of the Philadelphia (Ph) chromosome and/or the molecular evidence of BCR-ABL transcript. Accelerated/blastic phase (A/BP) diagnosis was made according to the IBMTR criteria.
The main clinical characteristics of patients and donors are summarized in Table 1 .
HLA typing. HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQA1, and DQB1 loci were identified by a combination of polymerase chain reaction (PCR) sequencespecific primers or sequence-based typing starting from genomic DNA isolated with the salting-out technique. 18, 19 To verify the reliability of the typing, we performed the HLA matching at two different times by repeat sampling of the donor and recipient pairs.
The minimum criteria for donor selection were A, B, DRB1 and DQB1 allele matches at the molecular level, even if typing of loci C, DQA1 and DRB3-4-5 was also performed. In case of no full matched donor, allele mismatches were allowed in classes I and II, while antigen mismatches were allowed only at locus C.
Conditioning regimen. The conditioning regimen was based on single fraction, low dose-rate TBI (10 or 8 Gy if cobalt 60 or a linear accelerator was used), cyclophosphamide 120 mg/kg and rabbit ATG (Fresenius, Bad Homburg, Germany) 15 mg/kg total dose (3 mg/kg/day, from days À6 to À2, over a 6-h infusion). Additional drugs were administered in case of A/BP: two patients received cytarabine (25 mg/kg by continuous infusion i.v. for four consecutive days), and five etoposide (35 mg/kg once i.v. on day À3).
GVHD prophylaxis and grading. GVHD prophylaxis consisted of cyclosporin-A plus a short course of methotrexate (days 1, 3, 6, 11). aGVHD and cGVHD were graded according to the Glucksberg et al 20 Relapse. Clinical relapse was defined as the reappearance of the disease at the hematological or clinical level; cytogenetic relapse was defined as at least one Philadelphia-positive metaphase after 6 months from transplant. Molecular relapse was defined as two consecutive positive PCR analyses, 3 months apart or earlier, depending on the quantity of transcript and the speed of increase, 6 months after transplant. 22, 23 Molecular monitoring. Molecular analysis of the ABL-BCR transcript was performed by nested-PCR as previously described 24 at 3-month intervals for the first 12 months and then every 6 months from 1 year onwards.
Supportive care. Patients were allocated in single, airpositive pressure rooms with HEPA-filtered air. Antiinfectious prophylaxis was accomplished with levoxacin and fluconazole during the transplant period and acyclovir until 9 months after transplant. In case of CMV antigenemia positivity, CMV pre-emptive therapy was administered using ganciclovir or foscarnet if ganciclovir was contraindicated or after resistance, defined as continuous positivity after 14 days therapy. Trimethoprimsulfamethoxazole prophylaxis was given twice weekly from engraftment to 6 months from BMT. All patients received filtered and irradiated blood products.
Statistical analysis. The analysis was conducted by the Kaplan-Meier method, 25 log-rank test 26 and proportional hazard regression model according to Cox 27 for censored data. w 2 test, Fisher's test and logistic regression were used for categorical variables, as appropriate. All data were updated to 20 November 2002. The analysis was performed by SPSS 9.0 software (Chicago, Inc.).
Results
HLA typing. Eight patients showed antigen mismatch at locus C: the mismatches were 'permissive' in three and nonpermissive in five patients, according to Ferrara et al. 28 Three such patients also showed additional allele mismatches (one at locus A, one at locus DQA, one at locus DQB1). Two showed an allele mismatch (both at DRB4) and one patient an antigen mismatch at locus DRB4. One patient showed two allele mismatches (loci A and DRB5).
ATG-related side effects. Side effects were generally mild and no cases of discontinuation occurred. The most frequent events observed were fever (16 patients), nausea and vomiting (nine patients), chills (seven patients), headache (two patients), pruritus (one patient) and skin rash (one patient).
Engraftment. The median number of nucleated cells infused was 4. Acute GVHD. aGVHD (Table 2 ) developed in 15 patients (54%). The median onset was at 30 days (range: 14-48 days). Six patients had grade I, three grade II and severe aGVHD (grade III-IV) occurred in six (21%); for three patients, GVHD represented the main cause of death (one with Crohn's disease died of intestinal grade IV aGVHD and two others developed grade IV aGVHD). As shown in Table 2 , age (cutoff 35.5 years, the median value) was the only variable that significantly affected the risk of aGVHD.
Chronic GVHD. cGVHD was evaluable in 25/28 patients (89%). The median onset was at 180 days (90-365 days). A total of 10/25 (40%) patients developed cGVHD, which was limited in 9/10. In only one patient (4%) cGVHD was extensive, and it involved the liver, mouth and gastrointestinal tract and was associated with a 'wasting' syndrome. The factors that were univariately and multivariately associated with cGVHD are shown in Table 3 . Briefly, advanced disease phase, interval diagnosis-transplant, a greater number of lymphocytes and total nucleated cells infused were univariately associated with an increased risk of cGVHD, whereas only the disease phase remained significant in multivariate analysis.
Survival, relapse and TRM. The 3-year survival of the entire series was 60.3 (95% CI 42.2-78.4%). For first CP patients, overall survival (Figure 1 ) was 76.2% (95% CI 58-94.4%); of the two patients in CP who relapsed, one experienced a molecular relapse 18 months after transplant and another a cytogenetic relapse 13 months after transplant and they are now in complete remission after therapy with imatinib mesylate. Disease phase at transplant, patients' age, interval between diagnosis and transplant, and the total number of infused cells affected survival in univariate analysis, as shown in Table 4 , whereas only age was significant in multivariate analysis. The reason why the phase of disease, which is one of the most obvious prognostic factors, did not result in a statistically significant value in the multivariate model is due, in addition to the low number of cases, to the statistically significant interaction between age and disease phase (median age of CP was 35 vs 44 years of AP).
In total, six relapses occurred: two were described above and four were hematological with blastic features; the latter occurred in patients transplanted in APs. Type and therapy of relapse and the outcome are shown in Table 5 . The median observation time of this cohort is 45.7 months for living patients (range 21.3-85.7 months). TRM was 22.3% at 1 year and 27.5% at 2 years, and age was significantly associated with TRM (P ¼ 0.02).
Death causes. A total of 11 patients died: four due to relapse (all had been transplanted in AP) and seven due to transplant-related causes. In particular, one patient, who also had Crohn's disease, died of intestinal grade IV aGVHD, three patients of opportunistic infections during aGVHD therapy, one patient of CNS infection, one with cGVHD of wasting syndrome and one for multiple organ failure.
CMV reactivation and disease. Seven of 13 CMV seropositive patients with a seropositive donor and five out of six seropositive patients with a seronegative donor reactivated CMV. Two of eight seronegative patients with a seropositive donor showed a CMV-positive antigenemia. Pre-emptive therapy with ganciclovir and/or foscarnet was was administered and no cases of CMV disease developed.
Discussion
Our study shows a reduced incidence of GVHD after unrelated adult transplants for CML, using low-dose ATG in the preparative regimen. Although this reduction applies to aGVHD and cGVHD, the latter was notably low, being limited and not requiring immunosuppressive therapy except for one patient. These findings contrast the high incidence of GVHD, which remains the major reason of morbidity and mortality after VUD transplants, observed in large series or single institution studies. Using conventional CsA/Mtx GVHD prophylaxis, the NMDP reported a 43% rate of grade II-IV aGVHD and a 33% rate for grade III-IV 10 for CML patients. With the same standard prophylaxis, the Seattle group reported 8 a 77% incidence of grade II-IV and 35% of grade III-IV aGVHD after unrelated transplants for CML. Our results, with aGVHD grade II-IV of 33% and III-IV of 22%, are more similar to the 20% grade III-IV recently reported after cord-blood unrelated transplants. 29 With respect to cGVHD, the incidence we observed was extraordinarily low -limited 36%, extensive 4%, -compared to the previously mentioned series, where it ranged from 60% in the NMDP series to 67% in Seattle, and again very similar to what was observed with cord-blood transplants. One way to reduce GVHD successfully is through T-cell depletion: within the NMDP series, T-cell depletion was associated with a lower relative risk of aGVHD and cGVHD, 10 but these effects were associated with an increased risk of leukemia relapse. An alternative way is represented by the use of polyclonal antilymphocyte antibodies. The mechanisms by which ATG could be effective in preventing GVHD are still not completely known. However, ATG is detectable in the serum of the patients not only during administration but also up to 3 weeks after transplant, resulting in an active interaction with both recipient's and donor's lymphocytes. 15, 30 In addition, high plasma levels of interleukin (IL)-4 and IL-10 and low levels of IL-2 and IFN were found in the first 2 weeks after transplantation in a subset of 10 of these patients (data not shown), showing a Th 0 -Th 2 polarization of lymphocytes: these findings could contribute to explain the low incidence of GVHD. 31 A high anti-CTLA4 specificity in the ATG preparation has also recently been demonstrated in these patients, 32 suggesting that ATG could act by downregulating the CD28-mediated stimulation of T-cells by an agonistic activation of the CTLA4 receptor. An additional mechanism in GVHD prevention could be that anti-CTLA4 antibodies could contribute to antibody-dependent cellmediated cytotoxicity (ADCC) by natural killer cells and macrophages via Fc receptors. Thus, combining the clinical data and the laboratory findings, it appears that low-dose ATG can induce sufficient functional modifications of T cells, resulting in a low incidence of GVHD. ATG has been used to facilitate the engraftment in transplants for aplastic anemia. 12, 13 Upon ATG treatment, the occurrence of GVHD seems to decrease, but the doses and the type of ATG that are best indicated in allogeneic stem cell transplantation for malignancies remains to be defined. The most widely used schedules employ 30-90 mg/kg ATG before transplant; 14, 15, [33] [34] [35] [36] the reported incidence of grade III-IV aGVHD ranges between 11 and 25%, results that are quite similar to ours with 15 mg/kg. In a dose-finding 20 and 120 mg/kg in 81 patients. They observed decreasing GVHD with higher doses, but more relapses in AP diseases, and concluded that 80 mg/kg appeared to be the optimal dose. Only one randomized study, 37 to our knowledge, has addressed the problem of the dose effect, showing a reduction of severe aGVHD with increasing doses of ATG (0 vs 7.5 vs 15 mg/kg) although accompanied by an increased risk of infections, thus resulting in similar survival among the different groups of patients. However, the type of ATG employed in that study 37 is different from the one used by us and the previously quoted studies, 14, 15, [33] [34] [35] [36] so direct comparisons are not possible.
A central point regarding the use of ATG in the transplantation of CML patients concerns the possible increase in relapse, as a direct consequence of T-cell modulation and less GVHD. The occurrence of relapse, even if our cohort is of small size, was mainly limited to advanced patients; unfortunately, such relapses were somewhat expected, considering that transplants in the AP of CML have about 50-80% risk of recurrence. Although there is no indication from our data of a higher than expected relapse rate in these patients, clearly new strategies are needed to address the problem of transplants in AP CML. Other groups, using the same type of ATG as us, also at higher doses, have not observed an increased relapse, except for the high doses of 80-120 mg/kg mentioned earlier. 16 It could be hypothesized that relapse has to do more with the type of ATG than with the dose. In fact, a high incidence of recurrences was reported in a study from the Huddinge Hospital. 15 They compared three different types of anti-T-cell antibodies, the rabbit ATG Fresenius, the thymoglobulin Sangstat (TMG) and OKT3 Orthoclone. The preparative regimen of TBI/cyclophosphamide and GVHD prevention with CsA/short MTX were used in the majority of patients. In CML, no relapses occurred in the 10 patients receiving ATG Fresenius or the 16 receiving OKT3, but the relapse rate was 61% with TMG Sangstat. The authors speculated that it could have been due to a more effective 'in vivo T depletion' of the graft by the remaining TMG antibodies. We think that the different antibody specificities can help explain such a wide different rate of relapse. In fact TMG exerts a strong anti-T activity, 17 thus being similar to a form of T depletion, while ATG has mainly anti-costimulatory molecule activity, 32 thus preventing immunocompetent cells from becoming activated. However, it should be remembered that polyclonal antibody preparations, which are obtained after immunization with different sources (T-cell lymphoblastic Jurkat line or human thymocytes), cover such a wide range of specificities that no conclusive statements can be made at the present time about which is best or most appropriate for different clinical situations.
Overall survival was affected by several obvious factors, such as age and phase of disease at transplant, resulting (for CP patients) in a probability of survival of 76% at 5 years. This is similar to what was reported by others with high doses of ATG 34 and similar to that seen after HLAmatched sibling transplants. Additionally, in view of the fact that our patients have almost absent cGVHD and a good quality of life without increased relapse, we suggest that VUD transplants using low-dose ATG represent a very effective strategy in the treatment of CML, particularly in CP.
